Since the disulfidptosis-related signature showed remarkable correlation with OS of glioma patients and harbored accurate prediction potential, we further explored the correlation between the disulfidptosis-related signature and clinicopathological features considering malignancy grade, IDH mutation, MGMT promoter methylation, and 1p19q codeletion status. The gene discussed is IDH1; the disease is glioma.